Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).

被引：0

作者：

Vitolo, Umberto

Merli, Michele

Norasetthada, Lalita

Wassenaar, Timothy Robert

Martin, Eva Maria Donato

Bobillo, Sabela

Shen, Biyi

Flink, Dina M.

Zhu, Min

Chandrasekharan, Soujanya

Brouwer-Visser, Jurriaan

Chaudhry, Aafia

Mohamed, Hesham

Ambati, Srikanth R.

Cordoba, Raul

机构：

[1] FPO IRCCS, Candiolo Canc Inst, Turin, Italy

[2] Osped Circolo Fdn Macchi, Varese, Italy

[3] Chiang Mai Univ, Div Hematol, Dept Internal Med, Fac Med, Chiang Mai, Thailand

[4] ProHealth Care, Waukesha, WI USA

[5] Hosp Univ Doctor Peset, Valencia, Spain

[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[7] Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst IIS FJD, Madrid, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7094

引用

页数：1